## 505298780 01/28/2019

# PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT5345557

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

## **CONVEYING PARTY DATA**

Name	Execution Date
JESUS MARIA BANALES ASURMENDI	06/20/2017
LUIS BUJANDA FERNANDEZ DE PIEROLA	06/20/2017
MARIA JESUS PERUGORRIA MONTIEL	06/20/2017
OIHANE ERICE AZPARREN	06/20/2017

## **RECEIVING PARTY DATA**

Name:	INTERCEPT PHARMACEUTICALS, INC	
Street Address:	10 HUDSON YARDS, 37TH FLOOR	
City:	NEW YORK	
State/Country:	NEW YORK	
Postal Code:	10001	

## **PROPERTY NUMBERS Total: 5**

Property Type	Number	
Application Number:	62321816	
Application Number:	62468259	
Application Number:	15484379	
PCT Number:	US1726931	
Application Number:	15711205	

## **CORRESPONDENCE DATA**

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

**Phone:** 6467572327

**Email:** ip.docketing@interceptpharma.com **Correspondent Name:** INTERCEPT PHARMACEUTICALS, INC.

Address Line 1: 10 HUDSON YARDS

Address Line 2: 37TH FLOOR

Address Line 4: NEW YORK, NEW YORK 10001

ATTORNEY DOCKET NUMBER: IPHA-035

NAME OF SUBMITTER: ANGEL L. MATOS

SIGNATURE: /Angel L. Matos/

DATE SIGNED:	01/28/2019	
Total Attachments: 5		
source=PATENT ASSIGNMENT (002)#page1.tif		
source=PATENT ASSIGNMENT (002)#page2.tif		
source=PATENT ASSIGNMENT (002)#page3.tif		
source=PATENT ASSIGNMENT (002)#page4.tif		
source=PATENT ASSIGNMENT (002)#page5.tif		

#### ASSIGNMENT

Jesús María Banales Asurmendi, Luis Bujanda Fernández de Pierola, María Jesús Perugorria Montiel, and Oihane Erice Azparren (each referred to as "Assignor") have made an invention(s) (the "Invention(s)") set forth in an application for patent of the United States, entitled <u>METHODS OF TREATING CANCER</u>, and which is a:

provisional application
(a) to be filed herewith; or
(b)  bearing Application No. 62/321,816, filed on April 13,
2016 and <b>62/468,259</b> filed on March 7, 2017;
non-provisional application
(a) to be filed herewith; or
(b)  bearing Application No. 15/484,379 and filed on April
11, 2017 ; and/or
PCT application
(a) bearing Application No. PCT/US17/26931 and filed on
April 11, 2017 .

WHEREAS, Intercept Pharmaceuticals, Inc, having its principal place of business at 10 Hudson Yards, 37<sup>th</sup> Floor, New York, NY 10001, USA (the "Assignee"), is desirous of acquiring the entire right, title, and interest in: the Invention(s); the application(s) for patent identified in paragraph (1), (2) and/or (3); the right to file applications for patent of the United States or other countries on the Invention(s); any application(s) for patent of the United States or other countries claiming priority to, and/or the benefit of, these applications; any provisional or other right to recover damages, including royalties, for prior infringements of these application(s); and any patent(s) of the United States or other countries that may be granted therefor or thereon.

NOW, THEREFORE, for good and sufficient consideration, the receipt of which is hereby acknowledged, and to the extent that the Assignor has not done so already via a prior agreement with the Assignee, or if the Assignor has already done so via a prior agreement with the Assignee then in confirmation of any obligation to do so in said prior agreement, the Assignor has sold, assigned, transferred, and set over, and by these presents does sell, assign, transfer, and set over, unto the Assignee, its successors, legal representatives, and assigns, the Assignor's entire right, title, and interest in:

- (a) the Invention(s);
- (b) the application(s) for patent identified in paragraph (1), (2) and/or (3);

- (c) the right to file applications for patent of the United States or other countries on the Invention(s), including all rights under the Hague Convention, the Paris Convention for the Protection of Industrial Property, and under the Patent Cooperation Treaty, and all rights of claiming priority in any country of the world;
- (d) any application(s) for patent of the United States or other countries claiming the Invention(s);
- (e) any application(s) for patent of the United States or other countries claiming priority to, and/or the benefit of, at least one of the application(s) for patent identified in paragraph (1), (2) and/or (3) or any application(s) for patent claiming the Invention(s), including any substitute application(s), division(s), continuation(s), and continuation(s)-in-part;
- (f) any provisional or other right to recover damages, including royalties, for prior infringements of any application for patent identified in the preceding paragraphs (b)-(e); and
- (g) any patent(s) of the United States or other countries that may be granted for or on any application for patent identified in the preceding paragraphs (b)-(e), including any reissue(s), reexamination(s), revival(s), renewal(s) and extension(s) of said patent(s).

The above-granted rights, titles, and interests are to be held and enjoyed by the Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, as fully and entirely as the same would have been held and enjoyed by the Assignor had this sale and assignment not been made.

The Assignor hereby represents to the Assignee, its successors, legal representatives, and assigns, that, at the time of execution and delivery of these presents, or if applicable, at such time said prior agreement was executed, the Assignor is a lawful owner of an undivided interest in the entire right, title, and interest in and to the Invention(s), that the Invention(s) are unencumbered, except, if applicable, by obligation to assign in accordance with said prior agreement, and that the Assignor has good and full right and lawful authority to sell and convey the same in the manner set forth herein, and that Assignor will not make or enter into any assignment, sale, agreement or encumbrance which would conflict with these presents.

The Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives, and assigns, that the Assignor will sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done in connection with any and all proceedings for the procurement, maintenance, enforcement and defense of the Invention(s), said application(s), and said patent(s), including interference and derivation proceedings, and any post-grant proceedings (e.g., opposition

proceedings, post-grant reviews, *Inter partes* reviews, supplemental examinations, etc.) without charge to the Assignor, its successors, legal representatives, and assigns, but at the cost and expense of the Assignee, its successors, legal representatives, and assigns.

The Assignor hereby authorizes and requests the attorneys of Intercept Pharmaceuticals, Inc. to insert in the spaces provided above the filing date, the application number, and the attorney docket number of the application(s) identified in paragraph (1), (2) and/or (3) when known.

The Assignor hereby requests the Commissioner of Patents to issue said patents of the United States to the Assignee for the sole use and behalf of the Assignee, its successors, legal representatives, and assigns.

Date: 20/06/2017 Jesus Maria Banales Asurmendi IN WITNESS WHEREOF, I, Oldane Exile Asfarem , hereby declare (Printed Name of Witness) that I was personally present and did see the abovenamed person duly sign and execute the assignment. (Signature of Witness) Date: 29/06/2017 Date: 20/06/2019 Luis Bujanda Fernández de Pierola By: named person duly sign and execute the assignment. (Signature of Witness)

Page 4 of 5

Attorney Docket No. IPHA-035/N01US

Page 5 of 5 Attorney Docket No. IPHA-035/N01US

Date: 20106/2017	By:	Motions Hussian
		María Jesús Perugorria Montie
IN WITNESS WHEREOF, I,	that I was perso	A farren, hereby onally present and did see the above.
(Signature of Witness)		
(Signature of Witness)		
Date: 20/66/2017	·,	
Date:20/06/2017	By:	
	· · · · · · · · · · · · · · · · · · ·	Oihane Erice Azparren
IN WITNESS WHEREOF, I, MARGE declare (Printed Name of Witness) named person duly sign and execute	that I was perso	onally present and did see the above-
Matris Kusan		
(Signature of Witness)		
Date: 26/06/2017		

PATENT REEL: 048153 FRAME: 0603

**RECORDED: 01/28/2019**